Smith & Nephew plc (SNN): what the price assumes

In the published model solve dated 2026-Q2, anchored at $30.12, Smith & Nephew plc (SNN) is priced for +6.4% growth. boothcheck publishes no house fair value, target price, or buy/sell rating; individual model outputs and user-controlled scenarios are analytical inputs, not Boothcheck targets. Narrative composed 2026-07-11.

Generated: 2026-08-10 · Exported: 2026-08-12 · Source: https://boothcheck.com/report/SNN

Headline

What The Price Assumes (Inversion)

The assumption today's price embeds, recovered by inverting the valuation.

The operating-margin figure is value-band context at year 12: derived from the framework's value band, a separate calculation — not part of the priced-in solve.

Solve inputs: computed at a 7.9% cost of capital with 4% terminal growth over a 5-year stage; each 1pp of cost of capital moves the implied operating-profit growth ~7.3pp.

Reconcile: at the x-ray's 9.3% required return this reads ~16.3%/yr; the models below use their own rates.

How unusual the bet is: within-range (limited comparison data)

Valuation X-Ray

The price is justified by relative-multiple and growth-DCF; asset-based/earnings-power land below the price.

How the valuation models price the stock relative to the market price. Price/FV above 1.0 means the market pays more than that lens defends (expensive); at or below 1.0 the lens can defend the price.

Families that justify the price: Relative, Growth Families that call it expensive: Asset, Earnings

The models below discount at their own flat-beta convention rates (cost of equity 9.3%, WACC 7.9%); the inversion above states its own rate.

Per-Model Detail (n=18)

Solvency

Bullet Takeaways

• Smith+Nephew closed its 12-Point Plan with the numbers it promised: 2025 revenue of $6.16 billion, trading margin up 160 basis points to 19.7 percent, free cash flow up 52.5 percent, and a portfolio spanning implants, robotics, sports medicine and wound care that its 20-F frames as "driving procedural innovation" (accession 0001104659-26-028258).
• The risk is a turnaround premium priced as durable compounding: at about 34 times record-basis operating income only the growth methods reach the quote, while China procurement (VBP) pressure and a deliberate 10.3 percent US knee decline ahead of the LANDMARK launch leave the growth premise resting on management forecasts.
• Watch the half-year results in early August 2026 against unchanged guidance of roughly 6 percent underlying revenue growth and $800 million free cash flow, plus execution of the new $500 million buyback.

Bull Case

Smith+Nephew's moat is procedural, not just physical: surgeons train on its systems, hospitals standardize around them, and the 20-F describes the Orthopaedics unit as "a leading portfolio of Hip and Knee Implants, robotics and digital-enabling technologies, driving procedural innovation" (accession 0001104659-26-028258). In trauma, the filing claims a structural edge inside a market it sizes at "over $15.7 billion annually", arguing the "simplicity and efficiency of our complete EVOS◊ Plating System gives us an advantage in the largest segment in Trauma" (accession 0001104659-26-028258). A surgeon who operates with a company's plating system, scopes with its arthroscopy towers, and closes with its wound care is expensive to dislodge, and that switching cost is what the growth-based methods are pricing when they, alone among the valuation families, reach today's quote.

The operational proof arrived with the 2025 results. Full-year revenue reached $6.16 billion, operating profit rose 20.7 percent, trading margin expanded 160 basis points to 19.7 percent, and free cash flow jumped 52.5 percent, closing out the 12-Point Plan transformation that since 2022 delivered a 5.7 percent reported revenue CAGR, 240 basis points of margin expansion, and a fifteen-fold increase in free cash flow. Management is now paying holders to stay: 2026 guidance calls for roughly 6 percent underlying revenue growth, about 8 percent trading profit growth, and around $800 million of free cash flow, with a new $500 million share buyback announced alongside the first-quarter update.

The first quarter's details support the trajectory more than the headline suggests. Underlying growth of 3.1 percent (4.7 percent adjusted for one fewer trading day) absorbed a deliberate 10.3 percent decline in US knees ahead of the LANDMARK knee launch, while US hips grew 5.8 percent on CATALYSTEM momentum and emerging markets grew 10.5 percent led by China, which management now expects to stop being a major headwind in 2026. That is a portfolio rotating toward its next product cycle while the two chronic bear items, China procurement pressure and US knee share, both show turning points. With the RISE strategy's 2028 targets promising acceleration in growth, profit, cash and returns, the bull case is a repaired compounder still priced with the skepticism it earned years ago.

Bear Case

Start with the balance sheet reads, because they frame how little slack the story has. Interest coverage runs at just 4.7 times trailing operating income, liquid assets stand at a modest $557 million for a $6 billion-revenue multinational, and the company has now committed $500 million to a buyback and an acquisition (Integrity Orthopaedics) in the same year it guides to $800 million of free cash flow. Nothing here is distressed, but the capital plan assumes the cash arrives on schedule from a business whose surgical volumes, pricing, and procurement environment are, as its own filing concedes, "ultimately controlled to a large extent by governments and healthcare systems" (accession 0001104659-26-028258). A margin stumble or a procurement shock does not threaten solvency; it threatens the buyback, the deal capacity, and the re-rating thesis all at once.

The pricing environment is the chronic structural drag. The 20-F states that success "depends on our ability to sell our products profitably, despite increasing" pricing pressure, and the annual report's own segment commentary shows what that looks like in practice: sports medicine and ENT growth "impacted in the second half of the year as the sector prepared for VBP", China's volume-based procurement regime (accession 0001104659-26-028258). Management says China stops being a major headwind in 2026, but that is a forecast about a policy regime it does not control. Meanwhile the first quarter's US knee decline of 10.3 percent, framed as a deliberate trade-off ahead of the LANDMARK launch, is still a double-digit share donation in its most visible market while competitors' robotic platforms keep enrolling surgeons.

The price has already banked the turnaround. At about 34 times record-basis operating income, the market pays for growth held near the self-funding ceiling for roughly six years, a pace only about a quarter of comparable growers sustained that long. Only the growth-based cash-flow methods reach the quote; peer multiples sit about 40 percent below it, and the earnings-power and asset-value reads sit at a third or less. That is a durability premium awarded to a company that spent four years in self-repair and now needs its new strategy to deliver acceleration on top of the repair. Transformation programs that end get replaced by new ones with three-year targets; RISE's 2028 goals are promises, and the multiple treats them as achievements. If 2026 delivers the guided 6 percent growth but the LANDMARK launch or China recovery disappoints, the growth family's premise weakens and the static frames far below become the market's fallback.

Valuation

What the price is betting: at $30.68 (July 10, 2026), the market pays about 34 times record-basis operating income, which inverts at an 8.8 percent cost of capital to operating growth held at the self-funding ceiling for roughly six years. The reference base rate is unflattering, with only about 26 percent of comparable fast growers sustaining that level for six years, and the comparison data is limited enough to treat the label directionally. But the guidance math frames what the market is actually underwriting: management targets roughly 6 percent underlying revenue growth and 8 percent trading profit growth for 2026, with the RISE strategy promising acceleration into 2028. The bet is that a completed turnaround compounds from here.

The methods split in the moat-premium pattern: only the growth-based cash-flow methods reach the price, and they land essentially on it. Peer multiples sit roughly 40 percent below the quote, earnings-power reads at about a third, and asset-anchored reads lower still. The filing-sourced inputs under the growth premise are specific: a trauma market the 20-F sizes at "over $15.7 billion annually" where the company claims a system-level advantage (accession 0001104659-26-028258), a hip and knee franchise built on "robotics and digital-enabling technologies" (accession 0001104659-26-028258), and 2025's delivered numbers, $6.16 billion of revenue with trading margin up 160 basis points to 19.7 percent and free cash flow up 52.5 percent. The first quarter's 3.1 percent underlying growth, with US knees down deliberately ahead of the LANDMARK launch and emerging markets up 10.5 percent, is the early-year checkpoint against those targets.

Solvency is serviceable rather than fortress-like: a modest net cash position on the measured basis, but interest coverage of only 4.7 times trailing operating income, and the new $500 million buyback plus the Integrity Orthopaedics acquisition spoken for against the guided $800 million of free cash flow. The share count has been flat to slightly declining. The decisive tension is simple: the growth methods that alone support the price are capitalizing management's 2026 to 2028 promises, and every quarterly trading update either funds that premium with delivered growth or leaves the static methods, sitting far below, as the only reads left standing.

Catalysts

The March 2, 2026 full-year report was the pivot event: 2025 revenue of $6.16 billion, operating profit up 20.7 percent, trading profit up 15.5 percent with margin reaching 19.7 percent, and free cash flow up 52.5 percent, alongside confirmation that the 12-Point Plan transformation is complete. Management layered on the RISE strategy, announced December 8, 2025, with 2028 targets for accelerating revenue growth, trading profit, free cash flow and adjusted ROIC.

The May 6, 2026 first-quarter update kept 2026 guidance unchanged, roughly 6 percent underlying revenue growth, about 8 percent trading profit growth (around $1.3 billion including the Integrity Orthopaedics acquisition), and approximately $800 million of free cash flow, and announced a $500 million share buyback. Inside the quarter: revenue of $1,501 million grew 3.1 percent underlying (4.7 percent adjusted for one fewer trading day), US hips grew 5.8 percent on CATALYSTEM, US knees fell 10.3 percent in what management called a deliberate trade-off ahead of the LANDMARK knee launch, and emerging markets grew 10.5 percent led by China, which management expects will no longer be a major headwind in 2026.

The forward calendar has three live items: the half-year results expected in early August 2026, where margin progress against the 19.7 percent base and buyback execution get their first full test; the LANDMARK knee launch ramp in the US, which has to convert the conceded first-quarter share into a product-cycle win; and continued China stabilization as the VBP rounds that dented sports medicine and ENT in late 2025 annualize out.

Peer Cohorts (Per Segment, With Filing Citations)

Core business (reported)

• ZBH (ZIMMER BIOMET HOLDINGS, INC.)
• FY2025 10-K: …for our knees, hips, and S.E.T. products, our major competitors include Johnson & Johnson MedTech (formerly the DePuy Synthes Companies of Johnson & Johnson), Stryker Corporation and Smith & Nephew plc. There are smaller competitors in these product categories as well that focus on smaller subsegments of the…
• FY2025 10-K: ") is our President and Chief Executive Officer . Our CODM allocates resources to achieve our operating profit goals through three operating segments. These operating segments, which also constitute our reportable segments, are Americas; EMEA; and Asia Pacific. Our CODM evaluates performance based upon segment…
• SYK (STRYKER CORP)
• FY2025 10-K: …products restricts competitors from duplicating these unique designs and features. We seek to obtain patent protection on our products whenever appropriate for protecting our competitive advantage. On December 31, 2025 we owned approximately 5,600 United States patents and approximately 9,000 patents in other…
• FY2025 10-K: …sales by 0.5% . Excluding the 0.7% impact of acquisitions and divestitures, net sales in constant currency increased by 8.7% from increased unit volume. The unit volume increase was due to higher shipments across all Orthopaedics businesses. Gross Pro fit Gross profit was $ 16,065 , $ 14,440 and $ 13,058 in 2025 ,…
• MDT (Medtronic plc)
• FY2025 10-K: …operating profit in the budget and forecasting process and to monitor budget and forecast variances versus actual when assessing segment performance and allocating capital resources to each segment. The accounting policies of the segments are the same as those described in Note 1. Certain depreciable assets may be…
• FY2025 10-K: …services from which the Neuroscience Portfolio segment derives its revenues include those focused on neurostimulation therapies and drug delivery systems for the treatment of chronic pain, as well as various areas of the spine and brain, along with pelvic health and conditions of the ear, nose, and throat. The…
• BDX (BECTON DICKINSON & CO)
• FY2025 10-K: …of Contents Notes to Consolidated Financial Statements - (Continued) Becton, Dickinson and Company The following tables include the significant expenses by segment that are regularly provided to the CODM and a reconciliation of segment operating income to Income from Continuing Operations before Income Taxes. Fiscal…
• FY2025 10-K: Solutions, and Biosciences units, some contracts also contain minimum purchase commitments of reagents or other consumables and the future sales of these consumables represent additional unsatisfied performance obligations of the Company. The revenue attributable to the unsatisfied minimum purchase commitment-related…
• RMD (ResMed Inc.)
• FY2025 10-K: …Care Software business for the year ended June 30, 2025 was $641.4 million, compared to $584.1 million for the year ended June 30, 2024, an increase of $57.3 million or 10%. The increase was driven by continued growth in the Home Medical Equipment, or HME, and MEDIFOX DAN verticals within our Residential Care…
• FY2025 10-K: …rates and financial markets. Our combined sales of medical devices into Iran, Russia and Ukraine did not constitute a material portion of our total revenue in fiscal year 2025. Further escalation of geopolitical tensions, or new geopolitical tensions, could have a broader impact that expands into other markets where…
• GEHC (GE HEALTHCARE TECHNOLOGIES INC.)
• FY2025 10-K: 8226; cost of production or delivery, whether due to geographic location, currency fluctuations, taxes, tariffs, duties, or otherwise, which may enable our competitors to offer greater discounts or lower prices; • the performance, capability, and integrity of third parties, including due to their financial instability…
• FY2025 10-K: …The increase as a percent of sales was driven by unfavorable mix within our service offerings, and cost inflation, including the impact of incremental tariffs, partially offset by an increase in pricing of our service offerings. Included in our total cost of revenues as part of our product investment was $490 million…
• BAX (BAXTER INTERNATIONAL INC)
• FY2025 10-K: …Products We currently manage our global operations based on three reportable segments: Medical Products & Therapies, Healthcare Systems & Technologies and Pharmaceuticals. The Medical Products & Therapies segment includes sales of our sterile IV solutions, infusion systems, administration sets, parenteral nutrition…
• FY2025 10-K: …higher allocation of corporate costs following the sale of our Kidney Care segment, higher costs related to tariffs, and higher accruals under our annual employee incentive compensation plans, partially offset by increased gross profit from higher sales and margin improvement projects. Pharmaceuticals Segment…
• STE (STERIS plc)
• FY2025 10-K: …to outsourced instrument reprocessing services. In addition, our procedural products also include endoscopy accessories, instruments, and capital equipment infrastructure used primarily in operating rooms, ambulatory surgery centers, endoscopy suites, and other procedural areas. Our AST segment supports medical…
• FY2025 10-K: …changes for comparability, as required. For more information, refer to Note 4 titled, "Discontinued Operations." Non-allocated operating costs that support the entire Company and items not indicative of operating trends are excluded from segment operating income. Our Healthcare segment provides a comprehensive…

Methodology Note

• Priced-in inversion: the valuation is inverted on the current price to recover the operating-income growth, duration, and steady-state margin the price embeds (ROE for financials, FFO growth for REITs).
• Valuation x-ray: the valuation models, grouped into four families (asset, earnings, relative, growth). Each model is expressed as a price/FV ratio (distance from price), not a point fair-value estimate. The spread across families is the disagreement.
• Solvency: net cash/debt, net-debt-to-NOPAT, interest coverage, and share-count CAGR from EDGAR financials (net debt / FFO and fixed-charge coverage for REITs; regulatory-capital framing for financials).
• Peer cohorts: per-segment comparables with deep-linkable SEC filing citations.

Fundamentals sourced from SEC EDGAR filings. Current price from Databento. The priced-in inversion and valuation x-ray are computed by the boothcheck engine; narrative composed by AI from the structured data.